Specialty Pharmacy

The FDA expanded the label for eltrombopag (Promacta) to now include indication for adults and pediatric patients 2 years and older with severe aplastic anemia in combination with standard immunosuppressive therapy.

The FDA has expanded the approved use of Seattle Genetics’ Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

The statement is intended to serve as a discussion guide for the risk factors, diagnosis, treatment and prevention of the disease.

NYU Langone Health discusses the challenges and benefits involved in starting or expanding a health system’s specialty pharmacy.

Study evaluates the association between body mass index in late adolescence and the incidence of pancreatic cancer in adulthood.

The FDA granted the designation to brentuximab vedotin (Adcetris) for this indication in combination with cyclophosphamide, doxorubicin, and prednisone.

Top news of the day from across the health care landscape.

Direct-acting antivirals are a costly but highly-effective class of drugs for the treatment of hepatitis C that can cure most cases.

Emgality (Galcanezumab-gnlm) is a self-administered once monthly subcutaneous injection and the third in its class for the preventative treatment of migraine in adults.

The new formulary will allow health plans to cover lower list price products, such as new authorized alternatives to brand-name medications.

Top news of the day from across the health care landscape.

One hundred percent of patients with hepatitis C virus genotypes 1, 2, 4, 5 and 6 achieved a sustained virologic response at 12 weeks post treatment with 8 weeks of glecaprevir/pibrentasvir treatment.

The FDA accepted a supplemental New Drug Application for olaparib’s (Lynparza) new indication for first-line maintenance treatment of advanced ovarian cancer.

Top news of the day from across the health care landscape

Sofosbuvir, velpatasvir, and voxilaprevir successful in patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence to direct-acting antiviral drug regimens.

Former New York Giants running back Tiki Barber discusses his mother's fight against breast cancer and his advocacy for cancer awareness.

The epidemiology of hepatitis A has shifted from point-source outbreaks to outbreaks caused by person-to-person transmission.

Top news of the day from across the health care landscape

Ron Lanton III, Esq., executive director and senior counsel for Frier Levitt Government Affairs, discusses how the growing number of PBM-owned specialty pharmacies could impact the pharmacy industry.

People who inject drugs may still able to achieve a cure of hepatitis C virus infection with treatment with direct-acting antivirals.

Testing DNA through plasma or urine rather than tissue offers health care providers an alternative method to evaluate potential treatment resistance.

The FDA approved Merck’s pembrolizumab (Keytruda) for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.

If approved, avatrombopag (Doptelet) would also be indicated for the treatment of chronic immune thrombocytopenia in patients who have had insufficient response to a previous therapy.

Top news of the day from across the health care landscape

Top news of the week from Specialty Pharmacy Times.

New data presented at the 2018 ACR/ARHP Annual Meeting shows that the treatment regimens for many patients are not being changed to reach a “treat-to-target” goal for low disease activity.